Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: WaferGen Shuffles Board; Spinomix Names Nahas as CEO


WaferGen Biosystems has shuffled and reduced the size of its board of directors to seven from nine following the firm's acquisition of IntegenX's next-generation sequencing library prep business.

Robert Schueren, IntegenX's CEO, will join WaferGen's board of directors. Prior to his role at IntegenX, Schueren was vice president and general manager of genomics at Agilent Technologies. The board also appointed William McKenzie as a director, effective Dec. 30, 2013. McKenzie most recently served as president and general manager of molecular diagnostics at PerkinElmer.

Scott Davidson and Joseph Pesce, representatives of Great Point Partners, stepped down from the board, as did Robert Coradini and Timothy Triche.

Swiss sample prep company Spinomix said this week that it has appointed Nasri Nahas as CEO.

Nahas was previously CEO of Geneva Bioinformatics, which he joined in 2011. Prior to that, Nahas held various scientific and business positions at biotech companies such as Genset and ValiGen.

Spinomix named Nahas as CEO in conjunction with an announcement that it had reached a milestone in its molecular diagnostics sample prep development plan, triggering an undisclosed second tranche payment from investor Debiopharm.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more